Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy
Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2016-11, Vol.6 (1), p.36870-36870, Article 36870 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 36870 |
|---|---|
| container_issue | 1 |
| container_start_page | 36870 |
| container_title | Scientific reports |
| container_volume | 6 |
| creator | Ho, Mary Woo, Donald C. F. Chan, Vesta C. K. Young, Alvin L. Brelen, Marten E. |
| description | Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naïve polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported. The baseline visual acuity was 0.65logMAR +/− 0.38 (Snellen 20/80 to 20/100). The visual acuity at 1 week, 3 months, 6 months and one year after treatment were significantly improved to 0.522logMAR+/− 0.365 (P |
| doi_str_mv | 10.1038/srep36870 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5111116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1841129450</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-40163cfd5a54bcf9bf4854b42717dffad3aa1a416c8f85683fc3e5cd98828f243</originalsourceid><addsrcrecordid>eNplkVtrFTEUhQdRbKl98A9IwBcVj-Y6k3kpSPEGBV_qc9iTS2dKZhKTTHH-vSmnPRx1v2TB_ljZe6-meUnwB4KZ_JiTjayVHX7SnFLMxY4ySp8e6ZPmPOdbXEvQnpP-eXNCO8llL9lpU66ThTLbpaDgUAx-i2Ey4JEeQ9qrO8h69SFCGTc0bCiOoQSzLTBPGpXRJojbewTOT4NN2saCYDHI2N8w2zJCDotFJU3R20f6RfPMgc_2_OE9a35--Xx9-W139ePr98tPVzstMC87jknLtDMCBB-06wfHZVWcdqQzzoFhAAQ4abV0UrSSOc2s0KaXkkpHOTtrLva-cR1ma3TdMoFXMU0zpE0FmNTfnWUa1U24U4LcV1sN3jwYpPBrtbmoecraeg-LDWtWRHJC6lEFrujrf9DbsKalrlepvme863pRqbd7SqeQa3LuMAzB6j5OdYizsq-Opz-Qj-FV4N0eyLW13Nh09OV_bn8AOCitQA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899347795</pqid></control><display><type>article</type><title>Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy</title><source>Nature Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Ho, Mary ; Woo, Donald C. F. ; Chan, Vesta C. K. ; Young, Alvin L. ; Brelen, Marten E.</creator><creatorcontrib>Ho, Mary ; Woo, Donald C. F. ; Chan, Vesta C. K. ; Young, Alvin L. ; Brelen, Marten E.</creatorcontrib><description>Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naïve polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported. The baseline visual acuity was 0.65logMAR +/− 0.38 (Snellen 20/80 to 20/100). The visual acuity at 1 week, 3 months, 6 months and one year after treatment were significantly improved to 0.522logMAR+/− 0.365 (P < 0.04) (Snellen 20/70), 0.363logMAR+/−0.382 (Snellen 20/50;P < 0.001), 0.377logMAR +/− 0.440 (Snellen 20/50;p = 0.005), and 0.35logMAR +/− 0.407 (Snellen 20/40;P < 0.001), respectively. The baseline central foveal thickness (CFT) on optical coherence tomography (OCT) was 394.7 +/− 70.6 μm. CFT at 6 months and 1 year after treatment were significantly reduced to 259 +/− 54 μm (p = 0.004) and 271 +/− 49.7 μm(p = 0.016), respectively. Triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone is an effective treatment for polypoidal choroidal vasculopathy. The majority of cases responded well with significant responses observed as early as 1 week after initiation of therapy.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep36870</identifier><identifier>PMID: 27848983</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/308 ; 692/699/3161/3175 ; Acuity ; Adult ; Aged ; Aged, 80 and over ; Anti-Inflammatory Agents - administration & dosage ; Asian Continental Ancestry Group ; Dexamethasone ; Dexamethasone - administration & dosage ; Drug Therapy, Combination - methods ; Female ; Follow-Up Studies ; Humanities and Social Sciences ; Humans ; Intravitreal Injections ; Lasers ; Macular Degeneration - drug therapy ; Macular Degeneration - pathology ; Male ; Middle Aged ; multidisciplinary ; Photochemotherapy - methods ; Photodynamic therapy ; Population studies ; Prospective Studies ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Recombinant Fusion Proteins - administration & dosage ; Science ; Steroids ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular diseases ; Visual Acuity</subject><ispartof>Scientific reports, 2016-11, Vol.6 (1), p.36870-36870, Article 36870</ispartof><rights>The Author(s) 2016</rights><rights>Copyright Nature Publishing Group Nov 2016</rights><rights>Copyright © 2016, The Author(s) 2016 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-40163cfd5a54bcf9bf4854b42717dffad3aa1a416c8f85683fc3e5cd98828f243</citedby><cites>FETCH-LOGICAL-c504t-40163cfd5a54bcf9bf4854b42717dffad3aa1a416c8f85683fc3e5cd98828f243</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111116/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111116/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27848983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ho, Mary</creatorcontrib><creatorcontrib>Woo, Donald C. F.</creatorcontrib><creatorcontrib>Chan, Vesta C. K.</creatorcontrib><creatorcontrib>Young, Alvin L.</creatorcontrib><creatorcontrib>Brelen, Marten E.</creatorcontrib><title>Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naïve polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported. The baseline visual acuity was 0.65logMAR +/− 0.38 (Snellen 20/80 to 20/100). The visual acuity at 1 week, 3 months, 6 months and one year after treatment were significantly improved to 0.522logMAR+/− 0.365 (P < 0.04) (Snellen 20/70), 0.363logMAR+/−0.382 (Snellen 20/50;P < 0.001), 0.377logMAR +/− 0.440 (Snellen 20/50;p = 0.005), and 0.35logMAR +/− 0.407 (Snellen 20/40;P < 0.001), respectively. The baseline central foveal thickness (CFT) on optical coherence tomography (OCT) was 394.7 +/− 70.6 μm. CFT at 6 months and 1 year after treatment were significantly reduced to 259 +/− 54 μm (p = 0.004) and 271 +/− 49.7 μm(p = 0.016), respectively. Triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone is an effective treatment for polypoidal choroidal vasculopathy. The majority of cases responded well with significant responses observed as early as 1 week after initiation of therapy.</description><subject>692/308</subject><subject>692/699/3161/3175</subject><subject>Acuity</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Asian Continental Ancestry Group</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Drug Therapy, Combination - methods</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Lasers</subject><subject>Macular Degeneration - drug therapy</subject><subject>Macular Degeneration - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Photochemotherapy - methods</subject><subject>Photodynamic therapy</subject><subject>Population studies</subject><subject>Prospective Studies</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Recombinant Fusion Proteins - administration & dosage</subject><subject>Science</subject><subject>Steroids</subject><subject>Tomography, Optical Coherence</subject><subject>Treatment Outcome</subject><subject>Vascular diseases</subject><subject>Visual Acuity</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkVtrFTEUhQdRbKl98A9IwBcVj-Y6k3kpSPEGBV_qc9iTS2dKZhKTTHH-vSmnPRx1v2TB_ljZe6-meUnwB4KZ_JiTjayVHX7SnFLMxY4ySp8e6ZPmPOdbXEvQnpP-eXNCO8llL9lpU66ThTLbpaDgUAx-i2Ey4JEeQ9qrO8h69SFCGTc0bCiOoQSzLTBPGpXRJojbewTOT4NN2saCYDHI2N8w2zJCDotFJU3R20f6RfPMgc_2_OE9a35--Xx9-W139ePr98tPVzstMC87jknLtDMCBB-06wfHZVWcdqQzzoFhAAQ4abV0UrSSOc2s0KaXkkpHOTtrLva-cR1ma3TdMoFXMU0zpE0FmNTfnWUa1U24U4LcV1sN3jwYpPBrtbmoecraeg-LDWtWRHJC6lEFrujrf9DbsKalrlepvme863pRqbd7SqeQa3LuMAzB6j5OdYizsq-Opz-Qj-FV4N0eyLW13Nh09OV_bn8AOCitQA</recordid><startdate>20161116</startdate><enddate>20161116</enddate><creator>Ho, Mary</creator><creator>Woo, Donald C. F.</creator><creator>Chan, Vesta C. K.</creator><creator>Young, Alvin L.</creator><creator>Brelen, Marten E.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161116</creationdate><title>Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy</title><author>Ho, Mary ; Woo, Donald C. F. ; Chan, Vesta C. K. ; Young, Alvin L. ; Brelen, Marten E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-40163cfd5a54bcf9bf4854b42717dffad3aa1a416c8f85683fc3e5cd98828f243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>692/308</topic><topic>692/699/3161/3175</topic><topic>Acuity</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Asian Continental Ancestry Group</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Drug Therapy, Combination - methods</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Lasers</topic><topic>Macular Degeneration - drug therapy</topic><topic>Macular Degeneration - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Photochemotherapy - methods</topic><topic>Photodynamic therapy</topic><topic>Population studies</topic><topic>Prospective Studies</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Recombinant Fusion Proteins - administration & dosage</topic><topic>Science</topic><topic>Steroids</topic><topic>Tomography, Optical Coherence</topic><topic>Treatment Outcome</topic><topic>Vascular diseases</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ho, Mary</creatorcontrib><creatorcontrib>Woo, Donald C. F.</creatorcontrib><creatorcontrib>Chan, Vesta C. K.</creatorcontrib><creatorcontrib>Young, Alvin L.</creatorcontrib><creatorcontrib>Brelen, Marten E.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ho, Mary</au><au>Woo, Donald C. F.</au><au>Chan, Vesta C. K.</au><au>Young, Alvin L.</au><au>Brelen, Marten E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2016-11-16</date><risdate>2016</risdate><volume>6</volume><issue>1</issue><spage>36870</spage><epage>36870</epage><pages>36870-36870</pages><artnum>36870</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>Polypoidal choroidal vasculopathy is a relatively common type of degenerative macular disease among the Chinese population. This study aims to describe the therapeutic responses to combination therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone in patients with polypoidal choroidal vasculopathy. A prospective series of 17 eyes of 13 patients suffering from treatment-naïve polypoidal choroidal vasculoapathy were recruited. All cases received triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone and one year outcomes were reported. The baseline visual acuity was 0.65logMAR +/− 0.38 (Snellen 20/80 to 20/100). The visual acuity at 1 week, 3 months, 6 months and one year after treatment were significantly improved to 0.522logMAR+/− 0.365 (P < 0.04) (Snellen 20/70), 0.363logMAR+/−0.382 (Snellen 20/50;P < 0.001), 0.377logMAR +/− 0.440 (Snellen 20/50;p = 0.005), and 0.35logMAR +/− 0.407 (Snellen 20/40;P < 0.001), respectively. The baseline central foveal thickness (CFT) on optical coherence tomography (OCT) was 394.7 +/− 70.6 μm. CFT at 6 months and 1 year after treatment were significantly reduced to 259 +/− 54 μm (p = 0.004) and 271 +/− 49.7 μm(p = 0.016), respectively. Triple therapy with photodynamic therapy, intravitreal aflibercept and intravitreal dexamethasone is an effective treatment for polypoidal choroidal vasculopathy. The majority of cases responded well with significant responses observed as early as 1 week after initiation of therapy.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27848983</pmid><doi>10.1038/srep36870</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2016-11, Vol.6 (1), p.36870-36870, Article 36870 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5111116 |
| source | Nature Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals; Free Full-Text Journals in Chemistry |
| subjects | 692/308 692/699/3161/3175 Acuity Adult Aged Aged, 80 and over Anti-Inflammatory Agents - administration & dosage Asian Continental Ancestry Group Dexamethasone Dexamethasone - administration & dosage Drug Therapy, Combination - methods Female Follow-Up Studies Humanities and Social Sciences Humans Intravitreal Injections Lasers Macular Degeneration - drug therapy Macular Degeneration - pathology Male Middle Aged multidisciplinary Photochemotherapy - methods Photodynamic therapy Population studies Prospective Studies Receptors, Vascular Endothelial Growth Factor - administration & dosage Recombinant Fusion Proteins - administration & dosage Science Steroids Tomography, Optical Coherence Treatment Outcome Vascular diseases Visual Acuity |
| title | Treatment of polypoidal choroidal vasculopathy by photodynamic therapy, aflibercept and dexamethasone triple therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T01%3A42%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20polypoidal%20choroidal%20vasculopathy%20by%20photodynamic%20therapy,%20aflibercept%20and%20dexamethasone%20triple%20therapy&rft.jtitle=Scientific%20reports&rft.au=Ho,%20Mary&rft.date=2016-11-16&rft.volume=6&rft.issue=1&rft.spage=36870&rft.epage=36870&rft.pages=36870-36870&rft.artnum=36870&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep36870&rft_dat=%3Cproquest_pubme%3E1841129450%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1899347795&rft_id=info:pmid/27848983&rfr_iscdi=true |